Publications list for Professor Douglas Joshua

2012 | 2011 | 2010 | 2009 | 2008 | 2007

2012

   
  • Brown, R., Suen, H., Favaloro, J., Yang, S., Ho, P., Gibson, J., Joshua, D. (2012), Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma. Oncoimmunology. 1(9), 1658-1660. [Abstract]
  • Brown, C., Larsen, S., Iland, H., Joshua, D., Gibson, J. (2012), Leukaemias into the 21st century: part 1: the acute leukaemias. Internal Medicine Journal. 42(11), 1179-1186. [Abstract]
  • Ho, P., Brown, R., Spencer, A., Jeffels, M., Daniher, D., Gibson, J., Joshua, D. (2012), Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial. Leukemia & Lymphoma. 53(9), 1728-1734. [Abstract]
  • Hsu, D., Wilkenfeld, P., Joshua, D. (2012), Multiple myeloma. BMJ (Online). 344(7840), d7953. [Abstract]
  • Brown, R., Kabani, K., Favaloro, J., Yang, S., Ho, P., Gibson, J., Fromm, P., Suen, H., Woodland, N., Nassif, N., Hart, D., Joshua, D. (2012), CD86+ or HLA-G+ myeloma cells are associated with poor prognosis and once acquired by trogocytosis create novel Tregacq cells. Blood. 120(10), 2055-2063. [Abstract]
  • Hsu, D., Wilkenfeld, P., Joshua, D. (2012), Multiple myeloma. BMJ. 344, d7953. [Abstract]
  • Ling, S., Lau, E., Al-Shabeeb, A., Nikolic, A., Catalano, A., Iland, H., Horvath, N., Ho, P., Harrison, S., Fleming, S., Joshua, D., Allen, J. (2012), Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. Haematologica. 97(1), 64-72. [Abstract]

2011

   
  • Mitsiades, C., Davies, F., Laubach, J., Joshua, D., San Miguel, J., Anderson, K., Richardson, P. (2011), Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(14), 1916-23. [Abstract]
  • Khoo, T., Vangsted, A., Joshua, D., Gibson, J. (2011), Interferon-alpha in the treatment of multiple myeloma. Current Drug Targets. 12(3), 437-446. [Abstract]
  • Brown, R., Langshaw, M., Uhr, E., Gibson, J., Joshua, D. (2011), The impact of mandatory fortification of flour with folic acid on the blood folate levels of an Australian population. Medical Journal of Australia. 194(2), 65-67. [Abstract]
  • Mo, S., Li, J., Loh, Y., Brown, R., Smith, A., Chen, Y., Joshua, D., Roufogalis, B., Li, G., Fan, K., Ng, M., Sze, D. (2011), Factors influencing the abundance of the side population in a human myeloma cell line. Bone Marrow Research. 2011, 1-8. [Abstract]

2010

   
  • Reid, S., Yang, S., Brown, R., Kabani, K., Aklilu, E., Ho, P., Woodland, N., Joshua, D. (2010), Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma. International journal of laboratory hematology. 32(6 Pt 1), e190-6. [Abstract]
  • Berenson, J., Anderson, K., Audell, R., Boccia, R., Coleman, M., Dimopoulos, M., Drake, M., Fonseca, R., Harousseau, J., Joshua, D., Lonial, S., Niesvizky, R., Palumbo, A., Roodman, G., San-Miguel, J., Singhal, S., Weber, D., Zangari, M., Wirtschafter, E., Yellin, O., Kyle, R. (2010), Monoclonal gammopathy of undetermined significance: a consensus statement. British Journal of Haematology. 150(1), 28-38. [Abstract]
  • Nath, C., Shaw, P., Trotman, J., Zeng, L., Duffull, S., Hegarty, G., McLachlan, A., Gurney, H., Kerridge, I., Kwan, Y., Presgrave, P., Tiley, C., Joshua, D., Earl, J. (2010), Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology. 69(5), 484-497. [Abstract]
  • Li, J., Sze, D., Brown, R., Cowley, M., Kaplan, W., Mo, S., Yang, S., Aklilu, E., Kabani, K., Loh, Y., Yamagishi, T., Chen, Y., Ho, P., Joshua, D. (2010), Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom's Macroglobulinaemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood. 115(17), 3580-8. [Abstract]

2009

   
  • Burgess, P., Robin, H., Langshaw, M., Kershaw, G., Pathiraja, R., Yuen, S., Coad, C., Xiros, N., Mansy, G., Coleman, R., Brown, R., Gibson, J., Holman, R., Hubbard, J., Wick, V., Lammers, M., Johnson, R., Huffman, K., Bell, J., Ibrahim, A., Estepa, F., Lovegrove, J., Joshua, D. (2009), Rule based processing of the CD4000, CD3200 and CD Sapphire analyser output using the Cerner Discern Expert Module. International journal of laboratory hematology. 31(0), 603-14. [Abstract]
  • Brown, R., Spencer, A., Ho, P., Kennedy, N., Kabani, K., Yang, S., Sze, D., Aklilu, E., Gibson, J., Joshua, D. (2009), Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leukemia and Lymphoma. 50(11), 1860-1864. [Abstract]
  • Palumbo, A., Sezer, O., Kyle, R., Miguel, J., Orlowski, R., Moreau, P., Niesvizky, R., Morgan, G., Comenzo, R., Sonneveld, P., Kumar, S., Hajek, R., Giralt, S., Bringhen, S., Anderson, K., Richardson, P., Cavo, M., Davies, F., Bladé, J., Einsele, H., Dimopoulos, M., Spencer, A., Dispenzieri, A., Reiman, T., Shimizu, K., Lee, J., Attal, M., Boccadoro, M., Mateos, M., Chen, W., Ludwig, H., Joshua, D., Chim, J., Hungria, V., Turesson, I., Durie, B., Lonial, S. (2009), International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 23(10), 1716-30. [Abstract]
  • Giralt, S., Stadtmauer, E., Harousseau, J., Palumbo, A., Bensinger, W., Comenzo, R., Kumar, S., Munshi, N., Dispenzieri, A., Kyle, R., Merlini, G., San Miguel, J., Ludwig, H., Hajek, R., Jagannath, S., Blade, J., Lonial, S., Dimopoulos, M., Einsele, H., Barlogie, B., Anderson, K., Gertz, M., Attal, M., Tosi, P., Sonneveld, P., Boccadoro, M., Morgan, G., Sezer, O., Mateos, M., Cavo, M., Joshua, D., Turesson, I., Chen, W., Shimizu, K., Powles, R., Richardson, P., Niesvizky, R., Rajkumar, S., Durie, B. (2009), International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 23(10), 1904-1912. [Abstract]
  • Dickinson, M., Prince, H., Kirsa, S., Zannettino, A., Gibbs, S., Mileshkin, L., O'Grady, J., Seymour, J., Szer, J., Horvath, N., Joshua, D. (2009), Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment. Internal medicine journal. 39(5), 304-316. [Abstract]
  • Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., Dimopoulos, M., Comenzo, R., Einsele, H., Barlogie, B., Anderson, K., Gertz, M., Harousseau, J., Attal, M., Tosi, P., Sonneveld, P., Boccadoro, M., Morgan, G., Richardson, P., Sezer, O., Mateos, M., Cavo, M., Joshua, D., Turesson, I., Chen, W., Shimizu, K., Powles, R., Rajkumar, S., Durie, B. (2009), International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 23(2), 215-224. [Abstract]

2008

   
  • Joshua, D., Brown, R., Ho, P., Gibson, J. (2008), Regulatory T cells and Multiple Myeloma. Clinical Lymphoma & Myeloma. 8(5), 283-286. [Abstract]
  • Loh, Y., Mo, S., Brown, R., Yamagishi, T., Yang, S., Joshua, D., Roufogalis, B., Sze, D. (2008), Presence of Hoechst low side populations in multiple myeloma. Leukemia & Lymphoma. , 1813-1816. [Abstract]

2007

   
  • Cooper, C., Joshua, D., Lee, C., Eyers, A., Cooper, W. (2007), Extranodal plasmablastic lymphoma arising in mantle cell lymphoma. Histopathology. 51(6), 856-9. [Abstract]
  • Sanders, J., Crawford, B., Gibson, J., Joy Ho, P., Iland, H., Joshua, D. (2007), Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS). International journal of laboratory hematology. , 395-397. [Abstract]
  • Ling, S., Campbell, L., Ho, J., Gibson, J., Joshua, D. (2007), Molecular Biology, Pathology, and Cytogenetics. In: Clinical Malignant Haematology. (pp.847-857).United States: McGraw Hill.
  • Osborne, R., De Abreu Lourenço, R., Dalton, A., Houltram, J., Dowton, D., Joshua, D., Lindeman, R., Ho, P. (2007), Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 10(6), 451-456. [Abstract]